The synthetic Multivulva (synMuv) genes comprise two classes of genes, Class A and Class B, that act in the determination of vulval precursor cell (VPC) fates (Ferguson, E.L. and Horvitz, H.R.,1985,1989). A synthetic Multivulva phenotype is produced by two mutations, one in each of the two classes of genes. Mutations in one or more class A genes or one or more class B genes do not produce a Multivulva phenotype. It has been proposed that the class A and class B genes define two functionally redundant pathways that act to specify the non-vulval fate of the vulval precursor cells. We have previously shown that
lin-13 behaves as a Class B SynMuv gene, a class that also includes genes encoding the tumor suppressor Rb and RbAp48, a protein that binds Rb. We have also shown that LIN-13 is a nuclear protein that contains multiple zinc fingers and a motif, LXCXE, that has been implicated in Rb binding. These results together suggested a role for LIN-13 in Rb-mediated repression of vulval fates. A Multivulva phenotype can in principle result from activation of a pathway or process that promotes vulval fates, or the inhibition of a pathway or process that represses vulval fates. Genes that influence this process can in principle act in an external signalling cell or in the VPCs. There have been two views to date. One view is that SynMuv genes act in an external signalling cell,
hyp7, to control expression of a factor that antagonizes the effects of the inductive signal or otherwise to promote nonvulval fates (Herman and Hedgecock 1990). The other view is that SynMuv genes act in the VPCs to repress transcription of genes that are involved in vulval differentation (Lu and Horvitz 1998). The proposal that SynMuv genes act in
hyp7 was based on genetic mosaic studies of a
lin-15 mutation that concomitantly removes both Class A and Class B activities (Herman and Hedgecock 1990), and was supported by mosaic analysis of the Class B SynMuv gene
lin-37 (Hedgecock and Herman 1995). Our findings that
lin-13::lacZ and LIN-13::GFP are consistently expressed in
hyp7 and are generally undetectable in VPCs at the time of VPC specification has been consistent with this view. If SynMuv genes act in
hyp7 and not in the VPCs, they may promote the expression in
hyp7 of an inhibitory factor that represses vulval fates. As it remains possible that some SynMuv genes act in
hyp7 while others act in the VPCs, and as expression data can be misleading as to cellular focus, we have undertaken genetic mosaic analyses of various SynMuv genes. We will report on our progress and plans concerning mosaic analysis of
lin-13 and
lin-35 and expression of SynMuv genes in specific cells.